Back to first-pass browser

First-pass extracted concept

gene-editing technologies for HIV-1 cure

Candidate: concept label1 source documents4 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

The review describes gene-editing technologies as approaches that can disrupt proviral DNA and deliver targeted therapies aimed at latent reservoirs and host viral receptors.

Source 1DOIPubMed

Resources required

The abstract supports that delivery is a key prerequisite and challenge for these approaches, but does not specify a particular editor, vector, or assay in the anchor source abstract.

Source 1DOIPubMed

What problem it solves

These approaches are presented as addressing persistent HIV-1 reservoirs and host dependency factors relevant to cure strategies.

Source 1DOIPubMed

What it does not solve

The abstract states that durability, accessibility, delivery, off-target effects, and practicality remain unresolved challenges for complete viral eradication.

Source 1DOIPubMed

Alternatives

The abstract contrasts gene editing with stem cell transplantation, broadly neutralizing antibodies, ultra-long-acting antiretroviral drugs, therapeutic vaccines, cell engineering, gene therapy, and immune-based molecular therapies.

Source 1DOIPubMed

Evidence Snippets

Among these, gene-editing technologies have shown promise in disrupting proviral DNA and delivering targeted therapies by targeting latent reservoirs and host viral receptors.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1challengesupports2026Source 1DOIPubMed

Complete HIV-1 viral eradication is challenged by durability, accessibility, delivery, off-target effects, and practicality.

Quoted textsource-backed
The challenges to achieve complete viral eradication include durability, accessibility, delivery, off-target effects, and practicality.
Claim 2limitationsupports2026Source 1DOIPubMed

Current HIV-1 cure approaches discussed in the review are not yet durable.

Quoted textsource-backed
However, none of these are durable.
Claim 3promisesupports2026Source 1DOIPubMed

Gene-editing technologies have shown promise for disrupting proviral DNA and delivering targeted therapies by targeting latent reservoirs and host viral receptors.

Quoted textsource-backed
Among these, gene-editing technologies have shown promise in disrupting proviral DNA and delivering targeted therapies by targeting latent reservoirs and host viral receptors.
Claim 4strategy effectsupports2026Source 1DOIPubMed

Combinatorial therapies with ultra-long-acting antiretrovirals, broadly neutralizing antibodies, or latency-reversing agents can reduce reservoir size and achieve durable viral suppression.

Quoted textsource-backed
All approaches, including combinatorial therapies with ultra-long-acting antiretrovirals, broadly neutralizing antibodies, or latency-reversing agents, which reduce reservoir size and achieve durable viral suppression, are discussed.